Results 71 to 80 of about 1,036,342 (307)

Antibody drug conjugates

Indian Journal of Medical and Paediatric Oncology, 2020
Antibody drug conjugates (ADCs) are chemically engineered drugs consisting of monoclonal antibody (mAb) and cytotoxic compound attached chemically by a linker. Upon attachment to a specific target antigen, ADC enters into the cell and payload is released,
Stalin Bala, Siva K Prasad
doaj   +1 more source

Antibody–drug conjugates harboring a kinesin spindle protein inhibitor with immunostimulatory properties

OncoImmunology, 2022
Antibody–drug conjugates (ADCs) are used to target cancer cells by means of antibodies directed to tumor-associated antigens, causing the incorporation of a cytotoxic payload into target cells.
Anette Sommer, Sandra Berndt, Hans-Georg Lerchen, Sabrina Forveille, Allan Sauvat, Dominik Mumberg, Guido Kroemer, Oliver Kepp   +7 more
doaj   +1 more source

High data-rate optical communication payload for CubeSats [PDF]

, 2020
Space industry has undergone a significant change over the last years. The development moved from large and costly spacecrafts to cost-efficient designs and shorter development times.
Rödiger, Benjamin, Rochow, Christoph, Fuchs, Christian, Arnold, Saskia, Schmidt, Christopher, Menninger, Christian, Wertz, Philipp, Grillmayer, Lukas   +7 more
core   +1 more source

Biphasic Co‐Delivery of Curcumin and 5‐FU using 3D‐Printed Dissolving Microneedles for Skin Cancer Therapy

Advanced Healthcare Materials, EarlyView.
Using pixel‐aware digital light processing, the authors created high‐resolution, dissolvable microneedles from a PEGDA/VP matrix. These microneedles encapsulate curcumin and 5‐fluorouracil and dissolve in the skin, co‐delivering drugs directly to tumours.
Rutuja N. Meshram, Dimitrios A. Lamprou
wiley   +1 more source

Antibody-drug conjugates in breast cancer: Progress and future directions

Cell Reports Medicine
Summary: Antibody-drug conjugates (ADCs) have transformed the treatment landscape of breast cancer, enabling targeted delivery of potent cytotoxic payloads to antigen-expressing tumor cells.
Alexandra Bili Newman, Senthil Damodaran, Funda Meric-Bernstam   +2 more
doaj   +1 more source

Making the Case for Organ‐on‐Chip Platforms in Long‐Acting Therapeutics Development

Advanced Healthcare Materials, EarlyView.
LATs release drug from a tissue‐resident depot over weeks to months, improving adherence, but their development is hampered by preclinical models that cannot reproduce the coupled tissue processes, sustained release, local microenvironment change, interstitial transport, immune and foreign‐body responses, and clearance that govern depot performance in ...
Charlie Gowans, Abdulwahhab Khedr, Panagiotis G. Georgiou, Nehir Arik, Ozlem Sen, Steve P. Rannard, Tom O. McDonald, Christos Tapeinos   +7 more
wiley   +1 more source

Antibody-drug conjugates targeting HER2 for the treatment of urothelial carcinoma: potential therapies for HER2-positive urothelial carcinoma

Frontiers in Pharmacology
Urothelial carcinoma (UC) is a common cancer characterized by high morbidity and mortality rates. Despite advancements in treatment, challenges such as recurrence and low response rates persist. Antibody-drug conjugates (ADCs) have emerged as a promising
Chia-Hsien Shih, Yu-Hua Lin, Yu-Hua Lin, Yu-Hua Lin, Hao-Lun Luo, Hao-Lun Luo, Wen-Wei Sung, Wen-Wei Sung, Wen-Wei Sung   +8 more
doaj   +1 more source

From Cell‐Derived Vesicles to Hybrid Nanovectors: Biological Membranes as Functional Blueprints for Gene Delivery

Advanced Healthcare Materials, EarlyView.
Biologically derived and hybrid nonviral nanovectors are examined as distinct but convergent design approaches. Integrating synthetic components with biologically functionalized membranes allows efficient interactions with complex cellular environments.
Clara Baldari, Claudia Leone, Gabriella Leccese, Claudia De Stradis, Alessandra Invidia, Concetta Quintarelli, Biagio De Angelis, Franco Locatelli, Giuseppe Gigli, Gabriele Maiorano, Ilaria Elena Palamà   +10 more
wiley   +1 more source

Blood–Brain Barrier Regulation: Evolving From Classic Strategies to Electrochemical Ion and Reactive Oxygen Species Control

Advanced Healthcare Materials, EarlyView.
Conventional therapies suffer from poor blood–brain barrier (BBB) penetration and disordered ion/reactive oxygen species (ROS) homeostasis, hindering precise neurological treatment. Electrochemical strategies achieve accurate spatiotemporal regulation of neural homeostasis.
Xiaokang Hu, Caiyu Liu, Meijun Pang, Zhiyuan Shi, Dong Ming, Xiuyun Liu   +5 more
wiley   +1 more source

Antibody-Drug Conjugates (ADCs) for Breast Cancer Therapeutic Landscape: Concept and Mechanisms of Action

Hematology/Oncology and Stem Cell Therapy
The concept of a “magic bullet” in oncology—first envisioned by Paul Ehrlich—has evolved into one of the most dynamic areas in precision cancer therapeutics: antibody–drug conjugates (ADCs).
Roberto Paz-Manrique, Joseph A. Pinto, Henry L. Gomez Moreno   +2 more
doaj   +1 more source